PPT-Multiple myeloma: What’s new?

Grace B Athas PhD MLS Department of pathology LSUHSC CLPC Spring seminar series 2018 Learning objectives Review pathophysiology and lab diagnosis of plasma cell neoplasms with a focus on Multiple Myeloma. What is smouldering myeloma? Smouldering myeloma (also known as asymptomatic myeloma) is a veryslow-growing type of myeloma. Myeloma, also known as multiple myeloma, is a type of bone marrow cancerari Our Dana-Farber Experience. Deirdre Foley & Matthew Murphy. Our . Dana-Farber Experience. Dr O Gorman (. MIRT . Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston). Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Dr Matthew Jenner. Consultant Haematologist. Southampton General Hospital . UK Myeloma Forum Autumn Day. 12 November 2014. Introduction. Why define high risk myeloma?. 3. Patient expectations. Outcomes vary widely between different patients. Multiple myeloma .The management of the newly diagnosed patient . Bone. Marrow. G,A,E. Plasma cell. Virgin B cell. Lymphoblast. Lymphoplasmacyte. Plasma blast. Germinal Center. SOMATIC. Pre-B cell. IgM. new treatment in the horizon. Dr Amin . I. slam . MB, MRCP UK , FRCPath UK. Consultant haematologist and . H. aemato. -Oncologist. Southend University Hospital NHS Foundation trust. Myeloma patients support group meeting. Study of . clinocopathological. profile and chromosomal abnormalities by FISH in newly diagnosed multiple myeloma. Investigator – Dr. . Sukanya. S K.. Guide: Dr. . Shivani. . Vignesh. .. Co-guide- Dr . Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has Starr Morning Report Austin Akers, MD Internal Medicine PGY-3 Patient is a 59 year old previously fit and active male in remarkably good health for his age who has experienced a rapid overall physical decline over the last 2-3 months Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. Can we do better?. [Hospital name]. [Date]. What is myeloma?. Cancer of plasma cells. Leads to:. Bone infiltration. - fractures (especially vertebral wedge fractures), hypercalcaemia. - pain. H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department . IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT.